Hanmi Pharmaceutical to Debut Second Muscle-Preserving Obesity Drug at ADA 2026

2026年5月27日

執筆 MinJeKim4 回閲覧

この記事の日本語訳は準備中です。以下は英語の原文です。

Hanmi Pharmaceutical to Debut Second Muscle-Preserving Obesity Drug at ADA 2026

What Hanmi is showing in New Orleans

Hanmi Pharmaceutical (KOSPI: 128940), one of Korea's largest domestic drugmakers, said on May 27 that it will present eight studies on two of its obesity drug candidates at the American Diabetes Association (ADA) annual meeting in New Orleans, Louisiana, on June 5–8, 2026. The headline disclosure is LA-MSTN (HM500197) — a peptide-based myostatin inhibitor designed to add muscle while patients lose fat — which Hanmi is unveiling for the first time at the conference, according to the company's announcement carried by Yonhap and ChosunBiz.

LA-MSTN joins LA-UCN2 (HM17321), Hanmi's existing "muscle-building" obesity candidate, giving the company a two-asset franchise aimed at the same clinical gap: the lean-mass loss seen with current GLP-1 weight-loss drugs.

Why a second muscle-focused asset matters

GLP-1 obesity drugs led by Novo Nordisk's Wegovy and Eli Lilly's Mounjaro deliver large weight reductions but also strip out muscle: about 20–40% of the weight lost on a GLP-1 is lean mass, according to Hanmi's own framing of the problem cited in coverage from Korea Biomedical Review (KBR). Patients also tend to regain weight quickly once they stop dosing — a durability problem that has opened the door for next-generation candidates.

Most rival muscle-preservation programs are built on antibodies or Fc-fusion proteins, which are large molecules that are harder to combine with a GLP-1 in a fixed-dose regimen, ChosunBiz reported. Hanmi designed HM500197 as a peptide — smaller, and in the company's framing easier to co-formulate or co-administer — using its in-house AI-driven structural modeling platform, HARP (Hanmi AI-driven Research Platform), per the same report.

For a New York portfolio manager, the question is whether this is a genuine differentiator or an ADA-poster narrative. The honest answer based on disclosed status: it is early, but it is no longer just one program. LA-MSTN becomes the fourth named asset in the H.O.P (Hanmi Obesity Pipeline) project, sitting alongside LA-UCN2, the triple-agonist HM15275, and the near-commercial efpeglenatide.

Where each asset actually is in the clinic

Efpeglenatide — Hanmi's GLP-1 receptor agonist, the most advanced asset. Phase 3 patient recruitment in Korea is complete, and Hanmi has pulled its commercial launch forward to the second half of 2026 from a previously projected first half of 2027, according to Korea Biomedical Review. The company has set up a dedicated commercialization task force, "EFPE-PROJECT-Seosa," launched on April 13, 2026, per Seoul Economic Daily. Hanmi has guided to annual sales exceeding ₩100 billion (~$71 million) and will self-produce the drug at its Pyeongtaek facility and direct-sell through its existing Korean sales network, per ChosunBiz and KBR.
HM15275 — a triple agonist hitting GLP-1, GIP and glucagon receptors; in U.S. Phase 2, per ChosunBiz.
LA-UCN2 (HM17321) — a UCN2 analog that selectively targets CRFR2 rather than GLP-1R, designed for fat loss with muscle gain. Hanmi filed an IND with the U.S. FDA in September 2025 and the asset is in Phase 1 in healthy volunteers; Hanmi's own investor-relations release targets commercialization by 2031.
LA-MSTN (HM500197) — peptide myostatin inhibitor making its data debut at ADA 2026; ChosunBiz characterizes it as a research-stage candidate with no disclosed IND yet.

The practical read: only efpeglenatide is close enough to revenue to move the 2026 P&L. The muscle-preservation story is a 2028+ asset class.

Sizing the prize, sized to what Hanmi actually says

The most concrete sales anchor in current sell-side commentary is Eugene Investment & Securities analyst Kwon Hae-soon's estimate that Korea's domestic obesity treatment market is worth roughly ₩1 trillion (~$730 million), into which efpeglenatide will launch in H2 2026 as the country's first domestically developed GLP-1 obesity drug, per Seoul Economic Daily.

Against Hanmi's own ₩100 billion-plus efpeglenatide sales goal, that implies the company is aiming for at least a ~10% share of the Korean obesity drug market in the early years of launch — meaningful, but a fraction of the global Wegovy/Mounjaro franchises now sized in the tens of billions of dollars annually. The muscle-preservation pipeline is what gives Hanmi a non-me-too story to take outside Korea, and ADA 2026 is the first venue where investors get to see whether the LA-MSTN data supports that claim.

Historical context: this is Hanmi's third ADA in the obesity story

Hanmi presented six obesity studies at ADA 2025, according to its own investor-relations press release, and unveiled HM17321 as a muscle-preservation candidate at ObesityWeek 2024, per KBR. ADA 2026's eight-study package is therefore an incremental scale-up, not a debut — the new variable is the LA-MSTN data and how head-to-head muscle and fat-mass figures land versus the lean-mass profile of standard GLP-1 therapy.

What to watch next

The specific catalyst is the LA-MSTN preclinical data set at ADA 2026, scheduled for the June 5–8 window. Beyond that, the near-term checkpoints are: (1) any IND filing announcement for HM500197 following the ADA presentations, (2) Korean Ministry of Food and Drug Safety (MFDS, Korea's drug regulator) approval and pricing for efpeglenatide ahead of the targeted H2 2026 launch, and (3) Phase 2 readouts for HM15275 in the U.S.

Choi In-young, head of Hanmi Pharmaceutical's Future Growth Division, said the company is "focused on developing innovative drugs that deliver healthy weight loss — reducing body fat while strengthening muscle," per ChosunBiz.

This article is for informational purposes only and does not constitute investment advice. All clinical timelines and commercial targets reflect company disclosures and may change.